Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Aiqin Zhike Granules (艾芩止咳颗粒) is an innovative Traditional Chinese Medicine (TCM) candidate developed by Beijing Jingshi Weikang Pharmaceutical Technology Co., Ltd. It is classified as a Class 1.1 new drug in China and is specifically indicated for the treatment of acute tracheobronchitis, particularly for patients presenting with the 'wind-heat transforming into toxin' syndrome. The formulation is designed to clear heat, ventilate the lungs, resolve phlegm, and suppress cough. Pharmacologically, it is intended to exert anti-inflammatory, expectorant, and antitussive effects. The drug has progressed into Phase 3 clinical trials in China to evaluate its efficacy and safety in reducing cough severity and phlegm production compared to placebo.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Aiqin Zhike Granules.